Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2021-06-10 00:16:55
Oslo, Norway, June 10, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical
company dedicated to the discovery and development of vaccines and novel
immunotherapies, announced today that its CEO, Michael Engsig, and Chief
Innovation & Strategy Officer, Agnete Fredriksen, will give a presentation of
Vaccibody at Goldman Sachs 42nd Annual Global Healthcare Conference on June 10,
2021 at 2.10 pm EDT / 8.10 pm CET.
The live presentation may be viewed here:
https://kvgo.com/gs-global-healthcare/vaccibody-june-2021. Further, the slide
presentation will be available on Vaccibody's website at
https://www.vaccibody.com
About Vaccibody
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies. The Company
develops vaccines for the treatment cancer and infectious diseases. Vaccibody's
vaccine technology specifically targets antigens to Antigen Presenting Cells,
which are essential for inducing rapid, strong and long-lasting antigen-specific
immune responses and elicit efficacious clinical responses. Its lead product
candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively
outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment
of melanoma, lung-, head and neck, renal-, and bladder cancer